OA
JUNO

Omega Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Omega Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-50,000
Closed -$3.03M – 122
2015
Q1 		$3.03M Hold
50,000
– – 0.05% 82
2014
Q4 		$2.61M Buy
+50,000
New +$2.24M 0.04% 74

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Omega Advisors's JUNO Position: Q2 2015 in Review

Omega Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2015, closing a stake of 50,000 shares — an estimated $3.03M sold.

Omega Advisors first reported a position in JUNO in Q4 2014 and held it in 2 quarters. The position peaked at $3.03M in Q1 2015. 154 funds tracked by Wall St. Rank hold JUNO as of Q2 2015.

  • Omega Advisors reported no remaining Juno Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Omega Advisors sold 50,000 Juno Therapeutics, Inc. shares in Q2 2015, an estimated $3.03M.
  • Omega Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
  • Omega Advisors's Juno Therapeutics, Inc. position peaked at $3.03M in Q1 2015.
  • 154 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2015.

Based on Omega Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.